WGS vs. Genotyping: What's Actually Worth Your Money in 2026?

The consumer DNA testing market has a vocabulary problem. "DNA test," "genetic test," "genome sequencing," and "genotyping" are used almost interchangeably in marketing materials, but they describe fundamentally different technologies that produce fundamentally different results. Understanding the distinction is the single most important thing you can do before spending money on any genetic testing service.

The Core Difference, Stated Plainly

Genotyping checks a pre-selected list of known positions in your DNA. It's fast, cheap, and looks at roughly 600,000–700,000 specific SNPs (single nucleotide polymorphisms) that have been associated with traits, ancestry markers, or health conditions in previous research. This is what 23andMe, AncestryDNA, and MyHeritage use.

Whole Genome Sequencing (WGS) reads your entire genome — every single base pair, in order, across all 23 chromosome pairs plus mitochondrial DNA. At 30× coverage, each position is read an average of 30 times for accuracy. This produces a complete dataset of over 6.4 billion base pairs.

What Genotyping Misses

The 700,000 positions that genotyping arrays check were chosen because they're common in the population and have known associations. That's a reasonable approach — until it isn't. Here's what falls through the cracks:

Rare variants. If you carry a mutation that isn't on the genotyping chip's pre-selected list, the test won't detect it. Most pathogenic mutations associated with rare diseases are, by definition, rare — and therefore less likely to be included on consumer genotyping arrays. WGS captures everything, including variants that have never been seen before.

Non-coding regions. Genotyping focuses heavily on coding regions (genes) and known regulatory SNPs. But the vast majority of your genome — roughly 98% — is non-coding. These regions contain enhancers, silencers, and other regulatory elements that control how and when your genes are expressed. Research increasingly links non-coding variants to cancer susceptibility, autoimmune conditions, and neurological disorders. Genotyping is blind to almost all of this.

Structural variants. Large insertions, deletions, duplications, and inversions — collectively called structural variants (SVs) — can have profound effects on gene function. Genotyping arrays detect some copy-number variants but miss many structural changes. WGS is far more sensitive to these.

Mitochondrial DNA. Your mitochondrial genome is small (about 16,500 base pairs) but important — it's involved in energy production and is exclusively maternally inherited. Some genotyping arrays include a handful of mtDNA markers, but WGS sequences the entire mitochondrial genome.

The Numbers, Side by Side

The Cost-Per-Insight Argument

At first glance, genotyping looks like the better value: $79–$229 versus $180–$430 for WGS. But that comparison ignores what you're actually getting for your money.

Genotyping gives you roughly 700,000 data points for ~$150 (midrange). That's about $0.00021 per data point. WGS on a Dante Labs flash sale gives you 6.4 billion data points for ~$180. That's about $0.000000028 per data point — roughly 7,500 times more cost-efficient.

Of course, not all data points are equally valuable. Many of those 6.4 billion positions will be unremarkable. But the ones that matter — the rare variant in a cancer gene, the pharmacogenomic variant that affects your drug metabolism, the structural variant that explains a family pattern — are precisely the ones that genotyping is designed not to find.

When Genotyping Still Makes Sense

There are three scenarios where genotyping remains the better choice:

Ancestry and relative matching. If your primary goal is to find living relatives or get an ethnicity estimate, 23andMe and AncestryDNA have databases of tens of millions of genotyped users. No WGS provider comes close to that database size. More users means more potential matches. The optimal strategy for serious genealogists is to get both: WGS for data depth, then upload results to genotyping platforms for database access.

Speed. If you need results in weeks rather than months, genotyping is significantly faster. Most genotyping services return results in 3–8 weeks. WGS typically takes 8–16 weeks.

Casual curiosity. If you want a quick overview of your ancestry composition and a few health trait reports without going deep, genotyping delivers a satisfying consumer experience at a lower price and faster turnaround.

The Hybrid Approach

For maximum coverage, the smartest approach in 2026 is to stack both methods. Start with whole genome sequencing from a provider like Dante Labs for the complete dataset and raw data access. Then upload your data to analysis platforms like SelfDecode or Promethease for deeper health interpretation. Finally, if relative matching and genealogy are important, take a separate genotyping test from AncestryDNA or 23andMe to access their larger databases.

Total cost for the full stack: roughly $250–$500, depending on sales and which services you choose. The result: 100% genome coverage, comprehensive health and pharmacogenomic reports, complete raw data for future analysis, and access to the largest genealogical databases in the world.

The Bottom Line

Genotyping reads a curated excerpt of your DNA. Whole genome sequencing reads the entire book. Both have their place, but as WGS prices approach genotyping prices — a convergence that's happening faster than most people realize — the value proposition increasingly favors the complete read.

If you can only do one test in 2026, whole genome sequencing gives you more data, more clinical utility, more future-proofing, and better cost-per-insight than any genotyping array. The gap in convenience (speed, database size) is real but narrowing. The gap in data completeness is permanent and structural — a genotyping chip will never capture what it wasn't designed to look for.